ACURA PHARMACEUTICALS, INC Intellectual Property Contracts & Agreements
6 Contracts & Agreements
- License Agreements (6 contracts)
- Third Amendment to the Amended License, Development and Commercialization Agreement is made and entered into as of February 28, 2022 by the Registrant and between Abuse Deterrent... (Filed With SEC on June 30, 2023)
- Amendment #2 to the License, Development and Commercialization Agreement is made and entered into as of June 17, 2021 by the Registrant and between Abuse Deterrent Pharma, LLC (Filed With SEC on June 30, 2023)
- Amended License, Development and Commercialization Agreement is made and entered into as of October 16, 2020 by the Registrant and between Abuse Deterrent Pharmaceuticals, LLC (Filed With SEC on March 31, 2021)
- License, Development and Commercialization Agreement is made and entered into as of June 28, 2019 by the Registrant and between Abuse Deterrent Pharmaceuticals, LLC (Filed With SEC on March 31, 2020)
- License, Commercialization and Option Agreement is made and entered into as of March 16, 2017 by and between MainPointe Pharmaceuticals, LLC (Filed With SEC on June 7, 2018)
- LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN ACURA PHARMACEUTICALS, INC. AND KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (Filed With SEC on November 2, 2007)
